The new delivery vehicle, known as FL0445-LNP, belongs to a class of microscopic particles that function somewhat like molecular containers. Lipid nanoparticles are assembled from fat-like molecules that form a protective structure around nucleic acids. Their outer surfaces are compatible with the watery environment of the body, while their lipid composition helps them interact with cell membranes. After being taken up by cells, the particles are designed to break down and release their cargo. This process allows the delivered mRNA or circular RNA to reach the cellular machinery responsible for translating genetic instructions into proteins.

The need for such protection arises from the inherent instability of linear mRNA. A conventional messenger RNA molecule has defined ends, including a cap structure that helps ribosomes recognize it and a tail that contributes to stability and translation. These same terminal regions, however, can also become targets for cellular enzymes that degrade RNA. Once the molecule is destroyed, protein production stops. This limited lifetime is useful for some applications, including transient vaccination, but it can be a disadvantage when a therapeutic protein needs to be produced over a longer period.

Circular RNA, or cirRNA, offers a different molecular architecture. Instead of having two exposed ends, the RNA strand is joined into a continuous loop. This configuration removes the terminal points that many degradation enzymes attack, potentially allowing the molecule to remain active in cells for longer periods. Because circular RNA lacks a natural stop point, ribosomes may repeatedly move around the loop and generate multiple copies of the encoded protein. Yet the structure also introduces a challenge: circular RNA does not naturally possess the cap-and-tail arrangement that makes linear mRNA highly efficient at initiating translation.

To address this limitation, Hiroshi Abe, Seigo Kimura, and colleagues at Nagoya University’s Integrated Research Consortium on Chemical Sciences and Department of Chemistry developed a capped circular RNA construct called Cap-cirRNA. The design retains the closed-loop structure associated with increased resistance to degradation while adding a cap-related feature intended to improve the initiation of protein synthesis. The researchers describe the approach as an effort to combine the durability of circular RNA with the strong translation performance of conventional mRNA. In principle, this could allow cells to produce a therapeutic protein efficiently without requiring repeated administration of unstable RNA molecules.

The team paired Cap-cirRNA with FL0445-LNP, a nanoparticle obtained from researchers at the Bioscience & Engineering Laboratories of FUJIFILM Corporation. A notable feature of the particle is the branched biodegradable chains within its ionizable lipid component. Conventional lipid nanoparticles often rely on lipids with more linear structures. By introducing branching, the researchers sought to create a more flexible internal environment capable of accommodating nucleic acids with different sizes, weights, and molecular shapes. That flexibility may be particularly important for circular RNA, whose geometry and physical properties differ from those of linear mRNA.

In comparative experiments, FL0445-LNP increased mRNA activity by approximately tenfold relative to conventional lipid nanoparticle formulations, while producing a negligible inflammatory response under the reported conditions. The finding is significant because inflammation remains an important consideration in RNA medicine. Lipid nanoparticles must be sufficiently active to deliver their cargo, but excessive immune stimulation can limit dosing, reduce tolerability, or complicate repeated treatment. A biodegradable and adaptable particle that combines efficient delivery with a restrained inflammatory profile could therefore be useful across several classes of nucleic-acid therapies.

For an initial therapeutic test, the researchers selected GLP-1, a peptide hormone that helps regulate blood glucose and appetite. Current GLP-1 medicines, including drugs used in obesity treatment, generally deliver the peptide or a peptide analogue directly through injection. An RNA-based strategy takes a different route: rather than supplying the finished protein, it provides cells with the genetic instructions needed to manufacture it. If those instructions remain active for an extended period, the approach could potentially reduce the frequency of injections. In the mouse experiments, FL0445-LNP successfully delivered both linear mRNA and Cap-cirRNA encoding GLP-1 and produced measurable biological activity.

Cap-cirRNA showed greater functional activity than the corresponding linear mRNA in the animal studies, although the researchers emphasize that the system requires further optimization before its therapeutic potential can be assessed in humans. Important questions remain concerning dose, tissue distribution, duration of protein production, immune responses after repeated administration, and the control of circular RNA activity. The amount of protein produced must also be carefully regulated, since prolonged or excessive expression could create safety risks depending on the therapeutic target. Nevertheless, the results provide evidence that a branched ionizable lipid nanoparticle can serve as a common delivery platform for chemically and structurally distinct RNA cargos.

The researchers envision applications extending beyond GLP-1 therapy. The platform could support next-generation vaccines in which durable protein production improves immune training, as well as cancer vaccines designed to present tumor-associated antigens to the immune system. It may also be relevant to genome-editing technologies, which require the temporary delivery of messenger RNA and editing components into cells. In genetic disorders caused by missing or defective proteins, the same strategy might provide instructions for producing a functional replacement protein. By pairing a versatile nanoparticle with RNA molecules engineered for either rapid or prolonged activity, the work points toward a broader toolkit for protein replacement, vaccination, and other forms of precision medicine.

Subject of Research: Cells

Article Title: A Branched Ionizable Lipid Nanoparticle Platform for Versatile In Vivo Delivery of Nucleic Acids: Validation from mRNA to Capped Circular RNA

News Publication Date: 19-Aug-2026

Web References: Nagoya University Integrated Research Consortium on Chemical Sciences: https://irccs.nagoya-u.ac.jp/ ; Nagoya University Department of Chemistry: https://www.chem.nagoya-u.ac.jp/en/

References: Cell Biomaterials, “A Branched Ionizable Lipid Nanoparticle Platform for Versatile In Vivo Delivery of Nucleic Acids: Validation from mRNA to Capped Circular RNA,” published 19-Aug-2026.

Image Credits: Sumeet Kulkarni, Nagoya University

Keywords: mRNA, circular RNA, Cap-cirRNA, lipid nanoparticles, FL0445-LNP, nucleic-acid delivery, GLP-1, RNA therapeutics, obesity treatment, cancer vaccines, genome editing, Nagoya University

At the core of this innovation lies the strategic modification of the ionizable lipid component within LNPs. These lipid nanoparticles serve as crucial delivery vehicles, encapsulating fragile mRNA molecules and escorting them safely into cells. The MIT team’s approach focused on synthesizing ionizable lipids with cyclic amino alcohol structures, coupled with ester groups designed to improve biodegradability and facilitate rapid clearance from the body once their job is done.

Conventional LNPs, including those used in COVID-19 vaccines developed by Moderna, typically require relatively high mRNA doses to elicit robust immune responses. However, the newly engineered lipid nanoparticles developed by the MIT scientists not only facilitate superior intracellular delivery but also efficiently overcome the cellular barrier known as endosomal entrapment. Following cellular uptake, LNPs are sequestered inside endosomes—membrane-bound compartments from which the payload must escape to reach the cytoplasm and prompt protein synthesis. The MIT particles exhibited a markedly improved ability to escape these endosomal compartments, ensuring more mRNA reaches its target location within the cell.

Another salient feature of these novel LNPs is their biodegradability, a direct consequence of incorporating ester bonds into the lipid tails. This design ensures that after delivering their mRNA cargo, the particles rapidly degrade into biocompatible byproducts, potentially minimizing inflammatory responses and other adverse effects commonly associated with nanoparticle accumulation.

The researchers validated the efficiency of their particles in preclinical studies, utilizing an mRNA vaccine targeting influenza in mice models. Remarkably, the optimized LNPs—designated AMG1541—elicited antibody titers equivalent to those induced by vaccines formulated with FDA-approved SM-102 lipids, yet at just one percent of the dose. This dose-sparing effect has monumental implications for vaccine accessibility and manufacturing scalability, particularly in low-resource settings where reducing raw material costs is critical.

Furthermore, AMG1541 demonstrated an enhanced affinity for antigen-presenting cells (APCs)—key orchestrators of the immune response tasked with antigen processing and presentation to lymphocytes. The augmented delivery to APCs likely amplifies immune activation, fostering a more efficient and robust protective response against pathogenic threats.

Beyond efficacy, the novel LNPs preferentially accumulate within lymphatic tissues such as lymph nodes, which serve as immunological hubs housing diverse immune cell populations. This targeted biodistribution further potentiates the immunostimulatory capacity of the vaccine by concentrating mRNA delivery where it most effectively triggers adaptive immunity.

An additional noteworthy advantage offered by mRNA vaccines is their rapid scalability and adaptability. Unlike traditional flu vaccines that require nearly a year for production due to reliance on egg-based culturing and strain selection logistics, mRNA-based formulations can be synthesized swiftly once circulating viral strains are identified. The development of highly potent delivery vehicles like AMG1541 could expedite this process even further by reducing the amount of mRNA needed per dose, enabling faster, cheaper, and more precise immunization campaigns tailored to seasonal influenza variants or emerging infectious diseases.

While the proof-of-concept experiments were conducted with influenza antigens, the versatility of this LNP platform could extend to other viral pathogens including SARS-CoV-2, HIV, and beyond. The technology’s superior delivery efficiency and safety profile make it an attractive candidate for a new generation of vaccines capable of addressing some of the most pressing infectious disease challenges.

Dr. Daniel Anderson, senior author and professor at MIT’s Department of Chemical Engineering, emphasized the broader implications of this work, highlighting how dose reduction can transform the economics and side effect profile of mRNA vaccines at a population scale. His team’s collaboration combined expertise spanning chemical engineering, immunology, and nanomedicine to achieve this feat, underscoring the interdisciplinary nature vital for advancing vaccine science.

This landmark study was published in the prestigious journal Nature Nanotechnology on November 7, 2025. It represents a significant leap forward in the field of vaccine delivery systems, demonstrating that rational lipid design informed by chemical structure-function relationships can overcome longstanding barriers in mRNA therapeutics.

The research received funding from Sanofi, the National Institutes of Health, and the Marble Center for Cancer Nanomedicine, alongside support from the Koch Institute at MIT. The lead authors, including Arnab Rudra, Akash Gupta, and Kaelan Reed, contributed key insights and experiments that paved the way for translating these novel lipid nanoparticles from bench to potential bedside applications.

As the world continues to grapple with emerging pathogens and seeks improved methods to control endemic infectious diseases, innovations like AMG1541 herald a new era in vaccinology. By enabling highly potent, dose-sparing, and rapidly deployable mRNA vaccines, such advanced lipid nanoparticle platforms could be pivotal in safeguarding global health against future pandemics.

Subject of Research: Development of enhanced degradable lipid nanoparticles for efficient delivery of influenza mRNA vaccines.

Article Title: Degradable cyclic amino alcohol ionizable lipids as vectors for potent influenza mRNA vaccines

News Publication Date: 7-Nov-2025

Web References: DOI: 10.1038/s41565-025-02044-6

Keywords: Vaccine development, vaccine research, life sciences, health and medicine, infectious diseases, influenza